Maksymilian Prondzynski

MSc, PhD

Investigator, BC Children's Hospital

Dr. Prondzynski's research focuses on understanding how the human heart forms before birth and what causes congenital heart diseases—structural problems that babies are born with. His team creates miniature human heart models in the laboratory to study these early developmental defects and find ways to detect, prevent, and potentially correct heart problems that begin in the womb. The research addresses critical questions about why some babies develop heart defects during pregnancy, even when their parents are healthy. By understanding what disrupts normal heart formation during early development, the team aims to identify risk factors and develop interventions that could help affected children. To achieve this, Dr. Prondzynski uses advanced laboratory techniques to grow human heart cells from stem cells—special cells that can become any type of cell in the body. His team can edit genes to understand how specific mutations cause birth defects, create 3D heart tissue that develops like an embryonic heart, and grow tiny organ-like structures called organoids that mimic how the human heart forms during pregnancy. These lab-grown models allow researchers to study congenital heart disease from the earliest stages without risk to mothers or babies. This innovative approach could lead to prenatal screening tools to detect heart defects earlier in pregnancy, new treatments to prevent or minimize developmental abnormalities, and potentially therapies to improve outcomes for children born with heart defects.

Academic Affiliations

  • Assistant Professor, , Department of Biomedical Physiology and Kinesiology, Faculty of Science, Simon Fraser University
  • Research Theme: Childhood Diseases
  • Research Group(s): Rare Diseases

Contact Information

Location

8888 University Drive, Burnaby, BC, Canada, V5A 1S6

Grants

Co-Primary Investigator. Using hiPSC-derived atrial tissue to understand better the role of SK ion channel variants in atrial fibrillation. Funding Source: CIHR

Co-Primary Investigator. Mechanisms by which thin filament variants induce hypertrophic cardiomyopathy. Funding Source: CIHR

Co-Investigator. Modeling human heart morphogenesis with bioreactor-derived cardiac organoids. Funding Source: Additional Ventures, Single Ventricle Research Foundation

Co-Investigator. Tissue Chips for Precision Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. Funding Source: National Center for Advancing Translational Sciences

Honours & Awards

2024 - Merit Abstract award, International Society for Stem Cell Research (ISSCR). Poster presentation of the project: “Suspension culture-derived organoid models of cardiac development”

2021 - Oral presentation award, Dr. M. Judah Folkman Research Day, Boston Children's Hospital, “Modeling of a novel Filamin-C mutation in hiPSC-derived cardiomyocytes resemble restrictive cardiomyopathy phenotypes”

2019 - Wilhelm P. Winterstein-Preis, German Heart Foundation, “Disease modeling reveals causative role for an Alpha-actinin 2 mutation and a diltiazem-reversible long QT phenotype in hypertrophic cardiomyopathy – an example of personalized medicine”

2018 - Young investigator award, International Society for Heart Research (ISHR), “CRISPR/Cas9 genome editing repairs a novel ACTN2 mutation and prevents the disease phenotype in human iPSC-derived cardiomyocytes and engineered heart tissue”

2017 - Prize for Doctoral Thesis, Cardiovascular Research Center (CVRC), “Modeling of hypertrophic cardiomyopathy and assessment of gene therapy in human iPSC-derived cardiomyocytes”

2015 - Poster prize, German Center for Cardiovascular Research. “2D culture of hiPSC-derived cardiomyocytes to evaluate molecular therapy and cell size”

Our Research

At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.

EXPLORE OUR RESEARCH

Stay in the Know

Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.

This field is for validation purposes and should be left unchanged.